Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.
Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.
This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.
Diane Abensur is a Franco-Israeli entrepreneur and the CEO & co-founder of Nanosynex. She established the company in 2017 after graduating from the Technion Institute of Technology International M.B.A (Haifa, Israel). She graduated from E.D.H.E.C Business School (Lille, France) and obtained her Master Degree in Business Management. In between, she worked as a junior analyst in consulting and M&A on healthcare deals in Paris and New York.
TechsoMed is an Israeli based medical device company, developing BioTrace™, a real-time, monitoring and control system for thermal ablation procedures. The technology is applicable to multiple fields such as Oncology (tumor ablation), Cardiac (arrhythmia) and Pain management. Our breakthrough technology (based on two granted patents) is the only one which can give physicians real time monitoring and control for ablation procedures, and it can do all that by interfacing with standard ultrasound devices. The control and security we can give physicians will make our system a must-have for major ablation treatments.
BioTrace™ - Transforming the way Thermal ablations are doneBioTrace – IO World’s first real time monitoring and control system for thermal ablation procedures such as solid tumors.
Interfacing with standard ultrasound devices that can be found in almost every clinic / hospital around the world.
Does not change the way the ablation procedure is done, allowing for fast regulatory approval.
Closed loop treatments with continuous feedback to measure therapy outcomes and to achieve the desired results.
successfully advanced through proof of concept , working prototype and clinical trials – 37 successful humans cases.
RetiCare IVS – Setting the sight on new treatments for retinal diseases
RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.
The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.
Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.
The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.
1 in 3 people will develop cancer during their lifetime, and over 90% of cancer patient deaths are caused when the cancer spreads though the body, a process called metastasis. We have identified an excellent anti-metastatic target for therapy development. Extensive pre-clinical models have shown therapeutic efficacy of targeting an enzyme called Lysyl oxidase (LOX). In addition, LOX expression is clinically correlated with metastasis and poor survival in cancer patients. Moreover, LOX is implicated in fibrosis and initial pre-clinical studies suggest LOX may also be an effective therapeutic target for limiting fibrosis. We are currently developing new antibodies against LOX that we are testing pre-clinically with the intention to move into clinical trials in human patients. Our work thus has great potential to develop new effective therapies of commercial value, and offers a real potential to impact on patient well being and survival.
Responsive Web Design powered by 